We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
- Authors
Lee, Amy Junghyun; Kim, Kyung Won; Cho, Young Chul; Ko, Yousun; Sung, Yu Sub; Shin, Youngbin; Lee, Jiwoo; Kim, Mi-hyun
- Abstract
We evaluated the incidence of pseudoprogression and indeterminate response (IR) in patients with lymphoma treated with immune checkpoint inhibitors (ICIs). A systematic search of PubMed and EMBASE was performed up to 6 February 2021, using the keywords "lymphoma," "immunotherapy," and "pseudoprogression." Random-effects models were used to calculate both pooled incidence of pseudoprogression patients with lymphoma and an IR according to LYRIC criteria, while the Higgins inconsistency index (I2) test and Cochran's Q test were used for heterogeneity. Eight original articles were included, in which the number of patients ranged from 7 to 243. Among the lymphoma patients with ICIs, the pooled incidence of pseudoprogression was 10% (95% confidence interval [CI]: 0.06–0.17). There was no publication bias in Begg's test (p = 0.14). Three articles were analyzed to determine the pooled incidence of pseudoprogression in patients with IR according to LYRIC criteria in a subgroup analysis, which was shown to be 19% (95% CI: 0.08–0.40). A significant proportion (10%) of patients with lymphoma treated with ICIs showed pseudoprogression, and 19% of patients with an IR response showed pseudoprogression and a delayed response. Immune-related response criteria such as LYRIC may be used for patients with lymphoma treated with ICIs.
- Subjects
LUGANO (Switzerland); IMMUNE checkpoint inhibitors; LYMPHOMAS; ANAPLASTIC lymphoma kinase; PUBLICATION bias; FALSE aneurysms
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 11, p2257
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10112257